'Rediscovered' lymphoma drug helps double survival: studyMedical XpressThe drug, bendamustine, more than doubled disease progression-free survival when given along with another therapy, rituximab (Rituxan), compared to the drug cocktail that…
Islet Sciences Announces Participation at the 2012 American Transplant Congress – Sacramento Bee
Islet Sciences Announces Participation at the 2012 American Transplant CongressSacramento BeeIslet Sciences will present an update on work with their xenotransplantation model for islet transplantation on June 5, 2012 at 5:30 PM ET. Islet Sciences is a…
Kids' Kidneys Can Work Well in Adult Recipients – Renal and Urology News
Kids' Kidneys Can Work Well in Adult RecipientsRenal and Urology NewsThe acute rejection rate at one year was 4%. The investigators concluded that transplant surgeons should be encouraged to use child donor kidneys, which frequently are discarded. …
Hélène Campbell 'dances' on Ellen DeGeneres show after double-lung transplant
Hélène Campbell, whose organ donation awareness campaign netted her an unexpected appearance three months ago on Ellen DeGeneres's daytime talk show, Ellen, was a return guest for the show's season finale.
Boston Scientific Secures FDA Approval For 32 MM, 38 MM Lengths – RTT News
Boston Scientific Secures FDA Approval For 32 MM, 38 MM LengthsRTT News(BSX: News ) said the US Food and Drug Administration, or FDA, has provided the company regulatory approval of 32 mm and 38 mm lengths for the PROMUS Element Plus Everolimus-Eluting…
Islet Sciences Announces Participation at the 2012 American Transplant Congress
NEW YORK, June 4, 2012 /PRNewswire/ — Islet Sciences, Inc., (OTCBB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation …
Boston Scientific Receives FDA Approval for 32 MM and 38 MM Lengths for PROMUS … – MarketWatch (press release)
Angioplasty.OrgBoston Scientific Receives FDA Approval for 32 MM and 38 MM Lengths for PROMUS …MarketWatch (press release)NATICK, Mass., June 4, 2012 /PRNewswire via COMTEX/ — The US Food and Drug Administration (FDA) has provided Boston Scientific …
ViroPharma initiates maribavir Phase 2 program for CMV infections
ViroPharma Incorporated today announced the initiation of a Phase 2 program to evaluate maribavir for the treatment of cytomegalovirus infections in transplant recipients.
From Earlier: Results from a Randomized Study of REVLIMID and Rituximab in … – Benzinga
From Earlier: Results from a Randomized Study of REVLIMID and Rituximab in …BenzingaCelgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), announced results from a randomized study comparing REVLIMID® (lenalidomide) plus ri…
ViroPharma announces initiation of clinical studies to evaluate maribavir
ViroPharma announced the initiation of a Phase 2 program to evaluate maribavir for the treatment of cytomegalovirus infections in transplant recipients. The planned program will consist of two independent …